BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 10828867)

  • 1. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
    Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
    Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients.
    Basara N; Blau WI; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
    Bone Marrow Transplant; 1998 Jul; 22(1):61-5. PubMed ID: 9678797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
    Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
    Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
    Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients.
    Baudard M; Vincent A; Moreau P; Kergueris MF; Harousseau JL; Milpied N
    Bone Marrow Transplant; 2002 Sep; 30(5):287-95. PubMed ID: 12209350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
    Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
    Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings.
    Vogelsang GB; Arai S
    Bone Marrow Transplant; 2001 Jun; 27(12):1255-62. PubMed ID: 11548843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus.
    Mookerjee B; Altomonte V; Vogelsang G
    Bone Marrow Transplant; 1999 Sep; 24(5):517-20. PubMed ID: 10482936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients.
    Hebert MF; Ascher NL; Lake JR; Emond J; Nikolai B; Linna TJ; Roberts JP
    Transplantation; 1999 Mar; 67(5):707-12. PubMed ID: 10096526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
    Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
    Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prophylaxis and treatment of chronic graft versus host disease].
    Huang K; Li Y; Huang SL; Fang JP; Zhou DH; Chen C
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):174-7. PubMed ID: 15833186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.
    Bornhäuser M; Schuler U; Pörksen G; Naumann R; Geissler G; Thiede C; Schwerdtfeger R; Ehninger G; Thiede HM
    Transplantation; 1999 Feb; 67(4):499-504. PubMed ID: 10071016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation.
    Hambach L; Stadler M; Dammann E; Ganser A; Hertenstein B
    Bone Marrow Transplant; 2002 Jun; 29(11):903-6. PubMed ID: 12080355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients.
    Basara N; Blau WI; Kiehl MG; Schmetzer B; Bischoff M; Kirsten D; Günzelmann S; Fauser AA
    Clin Transplant; 2000 Apr; 14(2):121-6. PubMed ID: 10770416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.